Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Merck's Write-Down Of Phase II Nuc Illustrates Current Reality In HCV

Feb 24 2017

• By Joseph Haas

Liver infection

Related Content

Will $2.5Bn Jury Verdict Against Gilead Stand? Future Royalties, Willful Infringement Penalty Uncertain

Dec 16 2016

Bristol Discontinues Development Of Inhibitex Nuc, Will Take $1.8 Billion Hit

Aug 24 2012

Bristol-Myers scoops Inhibitex for $2.5bn

Jan 09 2012

INFOGRAPHIC: Hepatitis C Market Still Has Room To Grow

Aug 01 2016

Gilead Offers Split Guidance For HCV; Expects Further Decline In 2017

Feb 08 2017

Merck in $3.85bn Idenix buy to bolster hep C outlook

Jun 09 2014

Nearing Finish Line, HCV Race Focuses On Salvage Therapy

Nov 24 2016

Sales Down, Discounts Up: Hepatitis C Market Feeling Zepatier Launch

May 13 2016

NICE Backs Hep C Drug Zepatier After Merck Offers Price Discount

Sep 08 2016

Related Companies

Merck & Co., Inc.

Gilead Sciences, Inc.

AbbVie Inc.

Idenix Pharmaceuticals, Inc.

Pharmasset, Inc.

Bristol Myers Squibb Company

Inhibitex, Inc.

Additional Topics

Business Strategies Commercial Deals Market Intelligence Infectious Diseases BioPharmaceutical

More from Strategy

More from Business

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window